GeNeuro ^Company

GeNeuro is a biotechnology company based in Switzerland that develops therapeutic drugs for nervous system diseases, particularly multiple sclerosis and schizophrenia. Their products include GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis, and they also develop diagnostic tests for retrovirus-ENV proteins in patients. The company's focus is on understanding and stopping the progression of neurodegenerative and autoimmune diseases, and their therapeutic candidate, temelimab, is a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family. GeNeuro was founded in 2006 and is a clinical-stage biopharmaceutical company.